Issue 1 - January 2026
Enabling access to pharmaceutical myopia control with the launch of the new low-dose Labtician Atropine
Labtician is proud to support the Canadian Association of Optometrists’ (CAO) policy position that endorses evidence-based myopia management as a standard of care for all at-risk patients¹. Labtician is enabling access to pharmaceutical myopia control with the launch of the new low-dose Labtician Atropine
Labtician Atropine provides eye care professionals with ready-to-use, precision-manufactured atropine drops to ensure consistent dosing. Available in four precise concentrations 0.01%, 0.02%, 0.025% and 0.05%, Labtician Atropine allows customization of treatment to patient needs and physician preference.
We provide direct-to-patient shipping anywhere in Canada through our pharmacy partners or your preferred retail pharmacy. For more information, email isrs@labtician.com
